Helsinn and Mundipharma China Pharmaceutical jointly announce NMPA’s approval of the oral formulation of Akynzeo® in China

Lugano, Switzerland, and Beijing, China, Sept 17 (Bernama-GLOBE NEWSWIRE) — Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Mundipharma China Pharmaceutical, the market leader in pain management, today jointly announce that the National Medical Products Administration (NMPA) has approved the oral formulation of Akynzeo^® for the treatment of chemotherapy-induced nausea and vomiting (CINV) in China.

http://mrem.bernama.com/viewsm.php?idm=35492